Does a higher platelet to lymphocyte ratio predict adverse outcomes in patients with acute coronary syndrome?
Higher platelet to lymphocyte ratio serves as a promising biomarker for predicting worse in-hospital and long-term prognosis in patients with acute coronary syndrome.
Recent studies have shown platelet to lymphocyte ratio (PLR) to be a potential inflammatory marker in cardiovascular diseases. We performed a meta-analysis to systematically evaluate the prognostic role of PLR in acute coronary syndrome (ACS). A comprehensive literature search up to May 18, 2016 was conducted from PUBMED, EMBASE and Web of science to identify related studies. The risk ratio (RR) with 95% confidence interval (CI) was extracted or calculated for effect estimates. Totally ten studies involving 8932 patients diagnosed with ACS were included in our research. We demonstrated that patients with higher PLR level had significantly higher risk of in-hospital adverse outcomes (RR = 2.24, 95%CI = 1.81-2.77) and long-term adverse outcomes (RR = 2.32, 95%CI = 1.64-3.28). Sensitivity analyses confirmed the stability of our results. We didn't detect significant publication bias by Begg's and Egger's test (p > 0.05). In conclusion, our meta-analysis revealed that PLR is promising biomarker in predicting worse prognosis in ACS patients. The results should be validated by future large-scale, standard investigations.
Li et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: